| Print
ARGENX SE (ARGX)
ARGENX SEThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Address
Willemstraat 5
Breda
NLD
4811
Telephone
+32 477 772944
Forecast key dates
| Name | Key Date |
|---|---|
| argenx SE Annual Report for 2025 | 2026-03-20T00:00:00 |
| argenx SE Fourth Quarter Earnings Conference Call for 2025 | 2026-02-27T08:30:00 |
| argenx SE Fourth Quarter Earnings Result for 2025 | 2026-02-27T00:00:00 |
| argenx SE Third Quarter Earnings Result for 2025 | 2025-10-30T00:00:00 |
| argenx SE Third Quarter Earnings Conference Call for 2025 | 2025-10-30T00:00:00 |
| argenx SE Second Quarter Earnings Result for 2025 | 2025-07-31T00:00:00 |
| argenx SE Second Quarter Earnings Conference Call for 2025 | 2025-07-31T00:00:00 |
| argenx SE Annual General Meeting for 2025 | 2025-05-27T00:00:00 |
| argenx SE First Quarter Earnings Result for 2025 | 2025-05-08T00:00:00 |
| argenx SE First Quarter Earnings Conference Call for 2025 | 2025-05-08T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.